Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia.

Belver L, Yang AY, Albero R, Herranz D, Brundu FG, Quinn SA, Pérez-Durán P, Álvarez S, Gianni F, Rashkovan M, Gurung D, Rocha PP, Raviram R, Reglero C, Cortés JR, Cooke AJ, Wendorff AA, Cordó V, Meijerink JP, Rabadan R, Ferrando AA.

Cancer Discov. 2019 Sep 13. doi: 10.1158/2159-8290.CD-19-0471. [Epub ahead of print]

PMID:
31519704
2.

The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer.

Lancho O, Herranz D.

Trends Cancer. 2018 Dec;4(12):810-822. doi: 10.1016/j.trecan.2018.10.003. Epub 2018 Nov 2. Review.

PMID:
30470303
3.

Sirt1 protects from K-Ras-driven lung carcinogenesis.

Costa-Machado LF, Martín-Hernández R, Sanchez-Luengo MÁ, Hess K, Vales-Villamarin C, Barradas M, Lynch C, de la Nava D, Diaz-Ruiz A, de Cabo R, Cañamero M, Martinez L, Sanchez-Carbayo M, Herranz D, Serrano M, Fernandez-Marcos PJ.

EMBO Rep. 2018 Sep;19(9). pii: e43879. doi: 10.15252/embr.201643879. Epub 2018 Jul 18.

4.

Relation between denaturation time measured by optical coherence reflectometry and thermal lesion depth during radiofrequency cardiac ablation: Feasibility numerical study.

González-Suárez A, Herranz D, Berjano E, Rubio-Guivernau JL, Margallo-Balbás E.

Lasers Surg Med. 2018 Mar;50(3):222-229. doi: 10.1002/lsm.22771. Epub 2017 Nov 23.

PMID:
29168554
5.

Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia.

Fabbri G, Holmes AB, Viganotti M, Scuoppo C, Belver L, Herranz D, Yan XJ, Kieso Y, Rossi D, Gaidano G, Chiorazzi N, Ferrando AA, Dalla-Favera R.

Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2911-E2919. doi: 10.1073/pnas.1702564114. Epub 2017 Mar 17.

6.

Synergistic antileukemic therapies in NOTCH1-induced T-ALL.

Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, Herranz D, Bansal M, Girardi T, Paietta E, Tallman MS, Rowe JM, De Keersmaecker K, Califano A, Ferrando AA.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2006-2011. doi: 10.1073/pnas.1611831114. Epub 2017 Feb 7.

7.

Glutaminolysis gets the spotlight in cancer.

Herranz D.

Oncotarget. 2017 Feb 14;8(7):10761-10762. doi: 10.18632/oncotarget.14384. No abstract available.

8.

Targeting NOTCH1 in T-ALL: Starving the dragon.

Herranz D, Ferrando AA.

Cell Cycle. 2016;15(4):483-4. doi: 10.1080/15384101.2015.1128191. Epub 2016 Feb 11. No abstract available.

9.

Evidence of the Missing Baryons from the Kinematic Sunyaev-Zeldovich Effect in Planck Data.

Hernández-Monteagudo C, Ma YZ, Kitaura FS, Wang W, Génova-Santos R, Macías-Pérez J, Herranz D.

Phys Rev Lett. 2015 Nov 6;115(19):191301. doi: 10.1103/PhysRevLett.115.191301. Epub 2015 Nov 3.

PMID:
26588370
10.

Novel catheter enabling simultaneous radiofrequency ablation and optical coherence reflectometry.

Herranz D, Lloret J, Jiménez-Valero S, Rubio-Guivernau JL, Margallo-Balbás E.

Biomed Opt Express. 2015 Aug 7;6(9):3268-75. doi: 10.1364/BOE.6.003268. eCollection 2015 Sep 1.

11.

Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.

Herranz D, Ambesi-Impiombato A, Sudderth J, Sánchez-Martín M, Belver L, Tosello V, Xu L, Wendorff AA, Castillo M, Haydu JE, Márquez J, Matés JM, Kung AL, Rayport S, Cordon-Cardo C, DeBerardinis RJ, Ferrando AA.

Nat Med. 2015 Oct;21(10):1182-9. doi: 10.1038/nm.3955. Epub 2015 Sep 21.

12.

Joint analysis of BICEP2/keck array and Planck Data.

Ade PA, Aghanim N, Ahmed Z, Aikin RW, Alexander KD, Arnaud M, Aumont J, Baccigalupi C, Banday AJ, Barkats D, Barreiro RB, Bartlett JG, Bartolo N, Battaner E, Benabed K, Benoît A, Benoit-Lévy A, Benton SJ, Bernard JP, Bersanelli M, Bielewicz P, Bischoff CA, Bock JJ, Bonaldi A, Bonavera L, Bond JR, Borrill J, Bouchet FR, Boulanger F, Brevik JA, Bucher M, Buder I, Bullock E, Burigana C, Butler RC, Buza V, Calabrese E, Cardoso JF, Catalano A, Challinor A, Chary RR, Chiang HC, Christensen PR, Colombo LP, Combet C, Connors J, Couchot F, Coulais A, Crill BP, Curto A, Cuttaia F, Danese L, Davies RD, Davis RJ, de Bernardis P, de Rosa A, de Zotti G, Delabrouille J, Delouis JM, Désert FX, Dickinson C, Diego JM, Dole H, Donzelli S, Doré O, Douspis M, Dowell CD, Duband L, Ducout A, Dunkley J, Dupac X, Dvorkin C, Efstathiou G, Elsner F, Enßlin TA, Eriksen HK, Falgarone E, Filippini JP, Finelli F, Fliescher S, Forni O, Frailis M, Fraisse AA, Franceschi E, Frejsel A, Galeotta S, Galli S, Ganga K, Ghosh T, Giard M, Gjerløw E, Golwala SR, González-Nuevo J, Górski KM, Gratton S, Gregorio A, Gruppuso A, Gudmundsson JE, Halpern M, Hansen FK, Hanson D, Harrison DL, Hasselfield M, Helou G, Henrot-Versillé S, Herranz D, Hildebrandt SR, Hilton GC, Hivon E, Hobson M, Holmes WA, Hovest W, Hristov VV, Huffenberger KM, Hui H, Hurier G, Irwin KD, Jaffe AH, Jaffe TR, Jewell J, Jones WC, Juvela M, Karakci A, Karkare KS, Kaufman JP, Keating BG, Kefeli S, Keihänen E, Kernasovskiy SA, Keskitalo R, Kisner TS, Kneissl R, Knoche J, Knox L, Kovac JM, Krachmalnicoff N, Kunz M, Kuo CL, Kurki-Suonio H, Lagache G, Lähteenmäki A, Lamarre JM, Lasenby A, Lattanzi M, Lawrence CR, Leitch EM, Leonardi R, Levrier F, Lewis A, Liguori M, Lilje PB, Linden-Vørnle M, López-Caniego M, Lubin PM, Lueker M, Macías-Pérez JF, Maffei B, Maino D, Mandolesi N, Mangilli A, Maris M, Martin PG, Martínez-González E, Masi S, Mason P, Matarrese S, Megerian KG, Meinhold PR, Melchiorri A, Mendes L, Mennella A, Migliaccio M, Mitra S, Miville-Deschênes MA, Moneti A, Montier L, Morgante G, Mortlock D, Moss A, Munshi D, Murphy JA, Naselsky P, Nati F, Natoli P, Netterfield CB, Nguyen HT, Nørgaard-Nielsen HU, Noviello F, Novikov D, Novikov I, O'Brient R, Ogburn RW, Orlando A, Pagano L, Pajot F, Paladini R, Paoletti D, Partridge B, Pasian F, Patanchon G, Pearson TJ, Perdereau O, Perotto L, Pettorino V, Piacentini F, Piat M, Pietrobon D, Plaszczynski S, Pointecouteau E, Polenta G, Ponthieu N, Pratt GW, Prunet S, Pryke C, Puget JL, Rachen JP, Reach WT, Rebolo R, Reinecke M, Remazeilles M, Renault C, Renzi A, Richter S, Ristorcelli I, Rocha G, Rossetti M, Roudier G, Rowan-Robinson M, Rubiño-Martín JA, Rusholme B, Sandri M, Santos D, Savelainen M, Savini G, Schwarz R, Scott D, Seiffert MD, Sheehy CD, Spencer LD, Staniszewski ZK, Stolyarov V, Sudiwala R, Sunyaev R, Sutton D, Suur-Uski AS, Sygnet JF, Tauber JA, Teply GP, Terenzi L, Thompson KL, Toffolatti L, Tolan JE, Tomasi M, Tristram M, Tucci M, Turner AD, Valenziano L, Valiviita J, Van Tent B, Vibert L, Vielva P, Vieregg AG, Villa F, Wade LA, Wandelt BD, Watson R, Weber AC, Wehus IK, White M, White SD, Willmert J, Wong CL, Yoon KW, Yvon D, Zacchei A, Zonca A; (BICEP2/Keck and Planck Collaborations).

Phys Rev Lett. 2015 Mar 13;114(10):101301. Epub 2015 Mar 9.

13.

An oncogenic enhancer enemy (N-Me) in T-ALL.

Herranz D, Ferrando AA.

Cell Cycle. 2015;14(2):167-8. doi: 10.4161/15384101.2014.989129. No abstract available.

14.

A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.

Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M, Llobet-Navás D, Cordon-Cardo C, Clappier E, Soulier J, Ferrando AA.

Nat Med. 2014 Oct;20(10):1130-7. doi: 10.1038/nm.3665. Epub 2014 Sep 7.

15.

GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.

Beiroa D, Imbernon M, Gallego R, Senra A, Herranz D, Villarroya F, Serrano M, Fernø J, Salvador J, Escalada J, Dieguez C, Lopez M, Frühbeck G, Nogueiras R.

Diabetes. 2014 Oct;63(10):3346-58. doi: 10.2337/db14-0302. Epub 2014 Jun 10.

16.

SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling.

García-Rodríguez JL, Barbier-Torres L, Fernández-Álvarez S, Gutiérrez-de Juan V, Monte MJ, Halilbasic E, Herranz D, Álvarez L, Aspichueta P, Marín JJ, Trauner M, Mato JM, Serrano M, Beraza N, Martínez-Chantar ML.

Hepatology. 2014 May;59(5):1972-83. doi: 10.1002/hep.26971. Epub 2014 Mar 31.

17.

Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.

Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, Sanchez-Martin M, Perez-Garcia A, Rigo I, Castillo M, Indraccolo S, Cross JR, de Stanchina E, Paietta E, Racevskis J, Rowe JM, Tallman MS, Basso G, Meijerink JP, Cordon-Cardo C, Califano A, Ferrando AA.

Cancer Cell. 2013 Dec 9;24(6):766-76. doi: 10.1016/j.ccr.2013.10.022. Epub 2013 Nov 27.

18.

Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer.

Wauters E, Sanchez-Arévalo Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J, Cowley MJ, Colvin EK, Njicop EN, Sutherland RL, Liu T, Serrano M, Bouwens L, Real FX, Biankin AV, Rooman I.

Cancer Res. 2013 Apr 1;73(7):2357-67. doi: 10.1158/0008-5472.CAN-12-3359. Epub 2013 Jan 31.

19.

Controlling shot noise in double-barrier magnetic tunnel junctions.

Cascales JP, Herranz D, Aliev FG, Szczepański T, Dugaev VK, Barnaś J, Duluard A, Hehn M, Tiusan C.

Phys Rev Lett. 2012 Aug 10;109(6):066601. Epub 2012 Aug 10.

PMID:
23006290
20.

SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency.

Herranz D, Maraver A, Cañamero M, Gómez-López G, Inglada-Pérez L, Robledo M, Castelblanco E, Matias-Guiu X, Serrano M.

Oncogene. 2013 Aug 22;32(34):4052-6. doi: 10.1038/onc.2012.407. Epub 2012 Sep 17.

PMID:
22986535
21.

Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK.

Maraver A, Fernández-Marcos PJ, Herranz D, Muñoz-Martin M, Gomez-Lopez G, Cañamero M, Mulero F, Megías D, Sanchez-Carbayo M, Shen J, Sanchez-Cespedes M, Palomero T, Ferrando A, Serrano M.

Cancer Cell. 2012 Aug 14;22(2):222-34. doi: 10.1016/j.ccr.2012.06.014.

22.

Acetylation is indispensable for p53 antiviral activity.

Muñoz-Fontela C, González D, Marcos-Villar L, Campagna M, Gallego P, González-Santamaría J, Herranz D, Gu W, Serrano M, Aaronson SA, Rivas C.

Cell Cycle. 2011 Nov 1;10(21):3701-5. doi: 10.4161/cc.10.21.17899. Epub 2011 Nov 1.

23.

Limited role of Sirt1 in cancer protection by dietary restriction.

Herranz D, Iglesias G, Muñoz-Martín M, Serrano M.

Cell Cycle. 2011 Jul 1;10(13):2215-7. Epub 2011 Jul 1.

24.

Free [NADH]/[NAD(+)] regulates sirtuin expression.

Gambini J, Gomez-Cabrera MC, Borras C, Valles SL, Lopez-Grueso R, Martinez-Bello VE, Herranz D, Pallardo FV, Tresguerres JA, Serrano M, Viña J.

Arch Biochem Biophys. 2011 Aug 1;512(1):24-9. doi: 10.1016/j.abb.2011.04.020. Epub 2011 May 7.

PMID:
21575591
25.

SIRT1 contributes to telomere maintenance and augments global homologous recombination.

Palacios JA, Herranz D, De Bonis ML, Velasco S, Serrano M, Blasco MA.

J Cell Biol. 2010 Dec 27;191(7):1299-313. doi: 10.1083/jcb.201005160.

26.

SIRT1: recent lessons from mouse models.

Herranz D, Serrano M.

Nat Rev Cancer. 2010 Dec;10(12):819-23. doi: 10.1038/nrc2962. Epub 2010 Nov 24. Review.

27.

Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer.

Herranz D, Muñoz-Martin M, Cañamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, Serrano M.

Nat Commun. 2010 Apr 12;1:3. doi: 10.1038/ncomms1001.

28.

Tunneling in double barrier junctions with "hot spots".

Herranz D, Aliev FG, Tiusan C, Hehn M, Dugaev VK, Barnaś J.

Phys Rev Lett. 2010 Jul 23;105(4):047207. Epub 2010 Jul 23.

PMID:
20867883
29.

Sirtuin 1 regulation of developmental genes during differentiation of stem cells.

Calvanese V, Lara E, Suárez-Alvarez B, Abu Dawud R, Vázquez-Chantada M, Martínez-Chantar ML, Embade N, López-Nieva P, Horrillo A, Hmadcha A, Soria B, Piazzolla D, Herranz D, Serrano M, Mato JM, Andrews PW, López-Larrea C, Esteller M, Fraga MF.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13736-41. doi: 10.1073/pnas.1001399107. Epub 2010 Jul 14.

30.

SIRT1 stabilizes PML promoting its sumoylation.

Campagna M, Herranz D, Garcia MA, Marcos-Villar L, González-Santamaría J, Gallego P, Gutierrez S, Collado M, Serrano M, Esteban M, Rivas C.

Cell Death Differ. 2011 Jan;18(1):72-9. doi: 10.1038/cdd.2010.77. Epub 2010 Jun 25.

31.

Impact of Sirt1 on mammalian aging.

Herranz D, Serrano M.

Aging (Albany NY). 2010 Jun;2(6):315-6. No abstract available.

32.

Adaptive Langevin sampler for separation of t-distribution modelled astrophysical maps.

Kayabol K, Kuruoglu EE, Sanz JL, Sankur B, Salerno E, Herranz D.

IEEE Trans Image Process. 2010 Sep;19(9):2357-68. doi: 10.1109/TIP.2010.2048613. Epub 2010 Apr 19.

PMID:
20409994
33.

Sirt1 protects against high-fat diet-induced metabolic damage.

Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9793-8. doi: 10.1073/pnas.0802917105. Epub 2008 Jul 3.

34.

Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.

Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz D, Vassilev LT, Serrano M.

Cancer Res. 2007 Aug 1;67(15):7350-7.

35.

Tumour biology: Policing of oncogene activity by p53.

Efeyan A, Garcia-Cao I, Herranz D, Velasco-Miguel S, Serrano M.

Nature. 2006 Sep 14;443(7108):159. No abstract available.

PMID:
16971940
36.

Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients.

Fuster D, Herranz D, Vidal-Sicart S, Muñoz M, Conill C, Mateos JJ, Martín F, Pons F.

Nucl Med Commun. 2000 Jul;21(7):623-6.

PMID:
10994664
37.

[Carbohydrate tolerance in normotensive hydrocephaly].

Cabezas-Cerrato J, Mata González P, Vázquez Herrero C, Herranz D, Ruiz Ocaña C, Durán Sacristán H.

Rev Clin Esp. 1981 Mar 31;160(6):397-9. Spanish. No abstract available.

PMID:
7019997

Supplemental Content

Loading ...
Support Center